INB-03

Secures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Program Ebstrocel for Epidermolysis Bullosa and Next-Generation Engineered Modalities Extending to 2045 BOCA RATON, Fla., July 01, 2026 (GLOBE NEWSWIRE) -- -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its CORDStrom™ platform patent application into the U.S. national phase before the United States Patent and Trademark Office (USPTO), advancing a key element of the Company’s global intellectual property strategy for its next-generation mesenchymal stromal cell (MSC) platform. Highlights Advanced to U.S. National Phase: The Company has officially transitioned its CORDStrom™ platform patent application into the U.S. national phase before the USPTO, solidifying its proprietary footprint in the world's largest healthcare market. De-Risked via Favorable PCT Written Opinion: During the international phase, the corresponding Patent Cooperation Treaty (PCT) application received a favorable Written Opinion regarding patentability, significantly validating the novelty, inventiveness, and strength of the underlying asset architecture prior to national entry. Broad Platform-Wide Protection: The application directly targets the Company’s CORDStrom™ mesenchymal stromal cell (MSC) platform, protecting Ebstrocel (pobistrocel) for epidermolysis bullosa (EB) alongside next-generation modalities designed to select MSCs based on disease-specific biology or engineer them to deliver targeted therapeutic payloads. Extended Commercial Runway: If granted, this foundational patent family is projected to provide exclusive commercial protection extending into at least 2045, establishing multi-decade market exclusivity and safeguarding long-term asset valuation. Global Expansion Strategy: In alignment with its international commercialization goals, the Company expects to pursue corresponding national and regional patent applications across additional high-value jurisdictions, including the United Kingdom, Europe, Asia, Latin America and other primary global markets. The U.S. national phase filing follows a favorable Written Opinion received during the international phase of the corresponding PCT application. The patent application is directed to the Company’s CORDStrom™ MSC platform, including Ebstrocel (pobistrocel) for epidermolysis bullosa (EB), as well as additional CORDStrom™ modalities in which MSCs are selected based on disease-specific biological characteristics and may be engineered to deliver targeted therapeutic payloads. The CORDStrom™ platform addresses historical industry bottlenecks such as donor-to-donor variability and batch manufacturing inconsistencies by leveraging a proprietary selection and pooled, allogeneic, human umbilical cord-derived framework. This newly advanced patent application protects not only the core therapeutic compositions but also the specialized engineering methodologies required to utilize MSCs as selective delivery vehicles for complex therapeutic payloads, creating an expansive defensive moat around the Company's cell therapy pipeline. “The submission of our CORDStrom™ platform patent application into the U.S. national phase represents another important milestone in building our intellectual property estate,” said Joshua Schoonover, General Counsel of INmune Bio. “This patent family, should it be granted, is expected to provide broad protection for the CORDStrom™ platform, including composition-of-matter, methods of treatment, and related intellectual property extending into at least 2045, subject to patent term adjustment and applicable patent laws. We remain on track to pursue corresponding patent protection in the United Kingdom, Europe, and other strategic jurisdictions worldwide. As we continue to expand the CORDStrom™ platform with new MSC compositions, engineered cell therapies, and indication-specific modalities, strengthening our global intellectual property portfolio remains a core strategic priority.” National phase entry is an important step under the Patent Cooperation Treaty (PCT) process. During this stage, patent offices in individual jurisdictions examine the application under applicable national or regional laws to determine whether patent claims may be granted. About CORDStrom™ CORDStrom™ is INmune Bio’s proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform designed to address the historical clinical challenges of donor variability and manufacturing inconsistency in MSC therapeutics. The platform is intended to enable scalable, tunable MSC products for inflammatory, immunologic, and degenerative diseases. Ebstrocel (pobistrocel), the Company’s lead CORDStrom™ product candidate, is being developed for epidermolysis bullosa (EB). Additional CORDStrom™ modalities may include MSCs selected based on disease-specific biological characteristics and engineered MSCs designed to deliver targeted therapeutic payloads. About INmune Bio Inc. INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. Moving beyond early-stage exploration, the Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes. INmune Bio is actively advancing two late-stage product platforms toward registrational milestones: CORDStrom™: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA and EU EMA in 2026, alongside a planned U.S. Biologics License Application (BLA) submission. XPro1595™: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform that selectively neutralizes soluble TNF (sTNF) to eliminate neuroinflammation without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease. To learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s intellectual property strategy; the potential prosecution, issuance, scope, term, validity, enforceability and geographic coverage of patent applications and any patents that may issue; expectations regarding corresponding national and regional patent applications; the potential protection of the CORDStrom™ platform, including composition-of-matter, methods of treatment, engineered cell therapies, disease-specific modalities and related intellectual property; expectations regarding potential patent protection extending into at least 2045; and the development, regulatory path, commercialization and potential clinical utility of the Company’s product candidates. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom™, XPro1595™ (XPro™, pegipanermin), and INKmune™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the U.S. Food and Drug Administration (FDA), the UK MHRA or any other regulatory body, and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any other regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to maintain, obtain, defend and enforce intellectual property rights; whether any pending patent applications will issue as patents or whether any issued patents will provide meaningful protection; the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release. INmune Bio Contacts: David Moss Chief Executive Officer (561) 710-0512 info@inmunebio.com Daniel Carlson Head of Investor Relations (415) 509-4590 dcarlson@inmunebio.com

Approval of pediatric strategy validates clinical data package and accelerates the regulatory path for CORDStrom™ in the United Kingdom BOCA RATON, Fla, June 25, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved the Pediatric Investigation Plan (PIP) for Ebstrocel™ for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB). The approval of the PIP is the first required stage toward a Marketing Authorization Application (MAA) submission in the United Kingdom. This regulatory milestone remains strictly aligned with the Company’s established timetable for an MAA filing in 2026 and a US filing for Accelerated Approval in early 2027. "We submitted the PIP for Ebstrocel expecting a ten-month review cycle, but requested an accelerated review based on the critical unmet need in RDEB," said Dr. Mark Lowdell, Chief Scientific Officer of INmune Bio. "The MHRA’s turnaround in under three months represents a clear endorsement of the clinical data package. Their constructive advice on minor adjustments to the phase 3 open-label trial protocol has already been integrated. This allows us to maintain our twin-track regulatory strategy: filing for conditional marketing authorization this year to enable early market access, while running the open-label registration trial in 2027 to satisfy post-marketing commitments for full marketing authorization." In the UK, EU, and U.S., all medicinal products seeking marketing approval must include an agreed-upon plan for pediatric delivery. The Ebstrocel™ PIP submission establishes the scientific justification for treating children with RDEB, characterized not merely as a skin condition but as a devastating systemic disease. The submission highlighted Ebstrocel’s potential to address the most debilitating symptoms reported by the patient community, specifically chronic wounds, intractable itch, and severe pain, which are the primary drivers of poor quality of life. With approximately 300 children affected by RDEB in the United Kingdom, part of a broader epidermolysis bullosa (EB) community of at least 5,000 individuals supported by DEBRA UK , this approval addresses a critical unmet medical need in a well-defined patient population facing substantial care burdens. The MHRA raised no objections to the clinical data or the claims presented in the submission. "Securing PIP approval ahead of schedule, together with the MHRA's written alignment across our CMC, non-clinical and clinical strategy, represents a significant regulatory de-risking milestone for Ebstrocel™ and the broader CORDStrom™ platform," said David Moss, CEO of INmune Bio. "Importantly, the MHRA has now reviewed and provided guidance across the key elements required for our planned 2026 Marketing Authorization Application, substantially reducing regulatory uncertainty as we move toward submission. The accepted meeting minutes from our face-to-face Scientific Advice meeting provide a clear roadmap for Conditional Marketing Authorization and establishes alignment on the evidence package, manufacturing transition strategy, and confirmatory trial design needed to support review. With these milestones achieved, we believe Ebstrocel is now positioned on a well-defined path to potential approval, bringing us closer to delivering the first systemic therapy designed to address the underlying disease burden of RDEB while creating a significant value inflection opportunity for shareholders as we move from late-stage development toward potential commercialization." The Company is now focused on its final preparations for the MAA submission and completing the final commercial manufacturing steps necessary for Ebstrocel™ authorization. About CORDStrom™ CORDStrom™ is a patent-pending cell medicine platform comprising aseptic, allogeneic, pooled human umbilical cord-derived mesenchymal stromal cells (hucMSCs) in suspension for injection or infusion. The CORDStrom™ platform leverages, among other things, proprietary screening, pooling and expansion techniques to create off-the-shelf, allogeneic, pooled hucMSCs as medicines to treat complex inflammatory and autoimmune diseases. CORDStrom™ products are designed to provide high-quality, off-the-shelf, batch-to-batch consistent, scalable, cGMP manufactured, potent cellular medicines that can be produced affordably and with repeatable specification. Pooling allows tuning of different CORDStrom™ products with different effector functions dependent upon selected donor characteristics. The platform enables creation of indication-specific products, which can be tuned for optimization of anti-inflammatory, immunomodulatory, wound healing, and other characteristics. The first of these is Ebstrocel™. About INmune Bio Inc. INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. Moving beyond early-stage exploration, the Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes. INmune Bio is actively advancing two late-stage product platforms toward registrational milestones: 1. CORDStrom™: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA and EU EMA in 2026, alongside a planned U.S. Biologics License Application (BLA) submission. 2. XPro1595™: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform that selectively neutralizes soluble TNF (sTNF) to eliminate neuroinflammation without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease. To learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit . Forward Looking Statements Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including trial results, timing of key milestones, future plans or expectations, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom™, XPro1595™ (XPro™, pegipanermin), and INKmune™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release. INmune Bio Contacts: David Moss Chief Executive Officer (561) 710-0512 info@inmunebio.com Daniel Carlson Head of Investor Relations (415) 509-4590 dcarlson@inmunebio.com